At the Nebraska Cancer Research Center in Lincoln, NE, we are committed to providing people local access to cutting-edge cancer research through clinical trials.
Since our inception, thousands of volunteers have participated in treatment, prevention and control trials, helping us identify more effective cancer treatments and improve the lives of cancer patients.
The Nebraska Cancer Research Center
The Nebraska Cancer Research Center has been a leader in cutting-edge cancer research since 1984. At NCRC, we provide local access to clinical trials sponsored by the National Cancer Institute. Since our inception, thousands of volunteers have participated in treatment, prevention and control trials through NCRC, helping us identify more effective cancer treatments and improve the quality of life for cancer patients.
Join us at the 4th annual "Colors of Hope" Cancer Research Fundraiser brought to you by Southeast Nebraska Cancer Center. The event will be held on August 24, 2017 at the Country Club of Lincoln. For more information click here.
New Clinical Trials
BR003: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple Negative Invasive Breast Cancer
RU011201l: A Randomized Phase III Trial of Eribulin Compared to Standard Weekly Paclitaxel as First- or Second-Line Therapy for Locally Recurrent or Metastatic Breast Cancer
RU0214071: Regorafenib Dose Optimization Stuy (ReDos): A Phase II Randomized Study of Lower Dose Regorafenib compared to Standard Dose Regorafenib in Patients with Refractory Metastatic Colorectal Cancer
EA6134: Advanced Mutant Melanoma - A Randomized Phase III trial of Dabrafenib + Trametinib followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma.
C-13 ARGO: A Phase III Randomized Placebo-Controlled Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients with Stage III Colon Cancer (ARGO)
RADIUS X: An open-label, multi-center, Expanded Treatment Protocol of Midostaurin (PKC412) in adult patients with newly diagnosed Frms-like tyrosine kinase receptor (FLT3) mutated Acute Myeloid Leukemia who are eligible for standard induction and consolidation chemotherapy